|
|
Kefar Hi-tech 2/5, Givat Ram Campus
Jerusalem, Jerusalem Israel
phone:(646) 240-4193
fax:
|
|
| Symbol |
ORMP |
| Exchange |
OTC |
| Founded |
2006 |
| Employees |
7 |
|
|
| oramed.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Develops technology for the oral delivery of drugs presently administered by injection |
|
| Management |
| Professor Avram Hershko, Scientific Advisory Board; Professor Ele Ferrannini, Scientific Advisory Board; Professor Barzilai, Scientific Advisory Board; Professor LeRoith, Scientific Advisory Board; Nadav Kidron, CEO and President; Dr Miriam Kidron, CSO and Board Member; Yifat Zommer, CFO; Leonard Sank, Board Member; Dr Harold Jacob, Board Member; Dr Ehud Arbit, Director or Research and Development; Dr Roy Eldor, Medical Affairs. |
| |
|
|
|
|
|
|
|
| Keywords |
| oral, oral drug delivery, oral insulin capsule, diabetes, drug delivery, injection |
|
|
|
| Description |
|
Oramed Pharmaceuticals is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an oral insulin capsule currently in Phase 2 trials, the Company is seeking to revolutionize the treatment of diabetes. Oramed's technology was is based on over 25 years of medical research at the world-renowned Hadassah University Medical Center in Jerusalem, Israel. |
|
| Products / Services |
Oramed's falgship product is an oral insulin capsules(ORMD-0801) which is based on the companys revolutionary proprietary technology. In addition to ORMD-0801, Orameds pipeline currently consists of an oral method for delivery of GLP1-Analog (ORMD-0901). Orameds unique oral delivery technology can further serve as a platform for other peptides, and additional applications of the Oramed technology have been identified.
|
|
| Technology / Differentiation |
Oramed's drug delivery technology is capable of significantly enhancing the absorption of peptides and proteins across the intestinal wall when delivered orally without modifying the active compounds. The delivery technology is based on incorporating several components or adjuvants consisting entirely of registered pharmacopoeial or GRAS excipients with a long history of pharmaceutical use in the formulation.
Oramed's oral insulin will be given as an earlier treatment and will lead to a healthier lifestyle for Diabetics. |
|
| Market / Customers |
Oramed Pharmaceuticals, has developed a revolutionary insulin delivery technology that will tap into the estimated $9 billion insulin market which leading epidemiologists agree will continue to grow at exponential rates in the coming years. The number of diabetics is also rising. In the US alone there are 23.6 million diabetics and it is estimated that there are 246 million diabetics worldwide.
|
|
| Status |
Oramed is currently conducting Phase 2b clinical trials on it's flagship product, an oral insulin capsule in South Africa. These trials are testing Orameds first indication on 30 type 2 diabetic patients. Results are expected at the end of the first quarter of 2010.
Phase 1a clinical trials are being conducted with an Oral GLP-1 analog and results are expected in the first quarter of 2010. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
